

Decision analysis of treatment options for vestibular schwannoma

Clinical article

**ROBERT G. WHITMORE, M.D.,¹ CHRISTOPHER URBAN, B.S.,¹ EPHRAIM CHURCH, B.A.,¹
MICHAEL RUCKENSTEIN, M.D.,² SHERMAN C. STEIN, M.D.,¹ AND JOHN Y. K. LEE, M.D.¹**

Departments of ¹Neurosurgery and ²Otorhinolaryngology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Object. Widespread use of MR imaging has contributed to the more frequent diagnosis of vestibular schwannomas (VSs). These tumors represent 10% of primary adult intracranial neoplasms, and if they are symptomatic, they usually present with hearing loss and tinnitus. Currently, there are 3 treatment options for quality of life (QOL): wait and scan, microsurgery, and radiosurgery. In this paper, the authors' purpose is to determine which treatment modality yields the highest QOL at 5- and 10-year follow-up, considering the likelihood of recurrence and various complications.

Methods. The MEDLINE, Embase, and Cochrane online databases were searched for English-language articles published between 1990 and June 2008, containing key words relating to VS. Data were pooled to calculate the prevalence of treatment complications, tumor recurrence, and QOL with various complications. For parameters in which incidence varied with time of follow-up, the authors used meta-regression to determine the mean prevalence rates at a patient with a unilateral tumor and partially intact hearing. The 3 treatment options, wait and scan, microsurgery, and radiosurgery, were compared.

Results. "Chvgtuetgppkpi" o qtg"vj cp"4722"cdvutcevu."v j g"cwv j qtu"wnvk o cvgn{ "kpenw fg f"335"ctvkengu"kp"v j ku"cpnc{ uku0" Recurrence, complication rates, and onset of complication varied with the treatment chosen. The relative QOL at the 5-year follow-up was 0.898 of normal for wait and scan, 0.953 for microsurgery, and 0.97 for radiosurgery. These fkhhtgtpegu"ctg"uk i pk l ecpr"r">"202274+0" F cvc"y g tg"vqq"uecteg"cv"vj g"32/{ gct"hqnnq y/wr"vq"ecnewncvg"uk i pk l ecpr" fkhhtg-ences between the microsurgery and radiosurgery strategies.

Conclusions. "Cv"7{"gctu. rcvkgpuvtgcvgf" ykvj" tcfkquwtigt{" jcxg" cp"qxgtcm" dgwvgt" SQN"vjcp"vjqug"vtgcvgf" ykvj" either microsurgery or those investigated further with serial imaging. The authors found that the complications associated with wait-and-scan and microsurgery treatment strategies negatively impacted patient lives more than the complications from radiosurgery. One limitation of this study is that the 10-year follow-up data were too limited to analyze, and more studies are needed to determine if the authors' results are still consistent at 10 years.

(DOI: 10.3171/2010.3.JNS091802)

KEY WORDS " " ' " " ceqwuwke"pgwtq o c" " ' " " xgukdwnc"uej y cppq o c" " ' " " fgekukqp"cpncfuku" " ' " " tcfkquwtigt{" " ' " " oketquwtigt{

VESTIBULAR schwannomas (acoustic neuromas) are benign tumors arising from the Schwann cells of the superior vestibular nerve. They represent 10% of all primary brain neoplasms and may be located intracanalicular, extracanalicular, or at the cerebellopontine angle.^{151,165} These tumors are usually slow growing and are diagnosed either because of symptoms such as unilateral hearing loss, tinnitus, and vertigo or as the result of incidental detection by MR imaging.⁷²

There are 3 treatment strategies available to patients with VS: “wait and scan” with serial MR imaging, microsurgical resection, or stereotactic radiosurgery.¹⁵⁸ Each treatment option has its own advantages and disadvantages, and most commonly the individual characteristics of a patient’s presentation are used to tailor the appropriate therapy. Expectant management avoids the complications of surgery and radiosurgery at the risk of tumor progression and irreversible neurological injury. Microsurgery offers the greatest immediate chance for cure but is associated with CSF leakage, facial nerve injury, and infection. Finally, radiosurgery is a noninvasive

Abbreviations used in this paper: QOL = quality of life; SF-36 = 36-Item Short Form Health Survey; VS = vestibular schwannoma.

treatment option for tumor control but may come with delayed complications from radiation toxicity and the need for additional microsurgery.

The goal of this study was to determine which treatment strategy yielded the highest QOL after 5 and 10 years of follow-up. To account for the multiple possible outcomes of a patient's treatment course, we developed a decision analytical model. The data for this model were derived from a meta-analysis of reports on the treatment of VS and on QOL following treatment.

Ogvyjqfu

Base Case

Because of the great variety of tumors and patients, we elected to limit the tumors for which this model is to be applied to no more than 2.5 cm in diameter, extracanalicular, and extending into the posterior fossa in a patient with at least some residual useful hearing (Fig. 1). Other than some hearing impairment, the hypothetical patient has no major tumor-related symptoms. Since several options have been proposed for this population, a critical comparison is of some practical importance in guiding patient treatment.

Management Strategies

The 3 strategies proposed most commonly in the literature are those of watchful waiting, termed wait and scan, microsurgery by the posterior fossa route (suboccipital or retromastoid approach), and radiosurgery (Gamma Knife or linear accelerator). Microsurgery performed through a translabyrinthine or middle fossa route was not included in this analysis because too few cases have been reported for this type of patient to allow statistically valid comparisons. Radiotherapy included single-dose treatments and fractionated protocols.

Data Collection

We derived the data for our analysis from a literature search of articles published between 1990 and June 2008. We searched MEDLINE, Embase, and the Cochrane database for English-language articles containing the key words "neuroma, acoustic" as a medical subject heading or related words, such as "vestibular schwannoma," "cer-gdgnnqrqpvkpg" cpi ng"vw o qt÷"cpf"qvjgtu"kp"vjg"vkvg" tgnf0" The search was expanded to include the terms "surgery," "radiotherapy," "radiosurgery," "therapy," and "complications" as either subheadings or titles. This search was supplemented using the "related articles" links in PubMed and by searching selected bibliographies manually.

The search yielded 2748 abstracts, of which 2127 were excluded. The excluded abstracts either lacked any original data or dealt with subjects unrelated to treatment outcomes. The remaining 621 articles were reviewed by 3 of the coauthors. Excluded from the 621 were 508 case series that lacked follow-up or followed fewer than 7 patients, those that dealt with bilateral, large (> 2.5 cm), intracanalicular, or other unusual vestibular tumors, or those that included patients who lacked useful hearing. We also culled these cases from larger, more inclusive,




FIG. 1. Coronal T1-weighted Gd-enhanced MR image demonstrating a VS of dimensions consistent with our base case.

series whenever possible. This left us with 113 articles, which provide the data for this decision analysis (Table 1 and Fig. 2).

In addition, searches were performed for health-related QOL associated with the presence of various complications, using "quality of life," "neuroma, acoustic," qt"urgek lē"eq o rnkecvkppu"cu"glvjgt"uwdjgcfkpiu"qt"vkvgul" This search yielded 27 relevant studies, listed in Table 2. Cnn"ugtkgu"wugf"kp"qwt"cpn{uku."kpenwfkpi"vjjug"eq o rct-ing different therapies, are nonanalytical and considered Level III evidence.⁵³

Decision Analytical Model

The decision analysis tree demonstrating the possible pathways and outcomes following treatment of a patient with VS is shown in Fig. 3. For a patient presenting with XU"cpf" tvkpi"vjg"fg tpkvqp"qh"qwt"dcug"ecug."3"qh"vjg"5" options is selected. Once treatment is chosen, the clinical course can be problem free, or complications can occur. Yg"fg tpg"eq o rnkecvkppu"cu"ej tqpkē"qt"rgt o cpgpv."cpf"kipqtg" o kpqt"qt"vtcpukgpv"fkhtēwmvkgu"gpeqwpvgtgf"kp"vjg" course of care (for example, hair loss). Complications, including death, can occur as the result of treatment or due to tumor growth or hemorrhage. The model ignores death due to other causes. Many studies documented as- { o rvq o cvke"vw o qt"i tqy vj."dww"qwt" o qfgn"fg tpgu"ōtgewt-rence" as growth that requires treatment by microsurgery or radiosurgery. Such "salvage" treatment is usually associated with poorer outcomes than outcomes associated with initial therapy.^{39,133} Chvgt"c"ikxgp"rgtkqf"qh"hqmqy/wr." the patient's health-related QOL is estimated, based on the effects of tumor recurrence or whatever complications may be present. The calculation of QOL is discussed below. Surgical complications are assumed to occur immediately; other complications are assumed to occur mid-way through the follow-up period.

The primary analysis involved calculating point esti-

TABLE 1: Complications after the wait-and-scan strategy, microsurgical treatment, and radiosurgical treatment for VS*

Complications	No. at Risk	Mean	95% CI	References
wait-and-scan strategy				
useful hearing loss	1427	0.528	0.40–0.64	10,14,19,36,43,45,60,88,89,98,103,106,110,120,136,139,144,152,160,164
facial numbness	168	0.016	0–0.02	45,152
vertigo, unsteadiness	617	0.225	0.16–0.26	43,45,111
tinnitus	199	0.176	0.10–0.24	111
hydrocephalus requiring shunt	317	0.038	0.02–0.04	20,112,123,162
other†	119	0.050	NC	45
required later treatment (05 yrs)	1842	0.238	0.17–0.30	2,10,14,19,36,43,45,47,60,88,89,98,101,103,105,110,112,121,123,126,136,138,139,145,147,152,161,164,167
likelihood later treatment is microsurgery	397	0.831	NC	
tumor-related deaths	2038	0.024	0.02–0.03	
microsurgical treatment				
useful hearing loss	1537	0.445	0.36–0.52	6,10,12,14,16,28,30,35,48,57,61,68–70,73,74,94,104,128,129,135,138,146
facial paralysis HB (Score VI)	2236	0.084	0.07–0.10	
facial weakness HB (Scores I–IV)	2229	0.142	0.10–0.18	
vertigo, unsteadiness	508	0.008	0–0.05	128
tinnitus	508	0.030	0–0.10	10,128
hydrocephalus requiring shunt	234	0.004	0–0.03	35,128
other‡	3927	0.117	NC	14,16,28,35,48,128,130
recurrence needing treatment				
05 yrs	617	0.027	0–0.07	13,14,28,35,69,102
010 yrs	617	0.054	0–0.14	
likelihood later treatment is microsurgery	5	0.80	NC	
periop & tumor-related deaths	2660	0.004	0.002–0.006	5,10,12–14,16,28,29,35,48,57,61,68–70,73,74,94,102,104,128,129,135,138,146
radiosurgical treatment				
useful hearing loss	2817	0.281	0.18–0.37	3,4,17,18,22,23,25,26,31,37,44,54–56,63,65–67,74,77,78,80,89,90,95,97,107,109,116,119,132,134,141,143,151,154,157,159,169,170
facial paralysis (HB Grade VI)	1291	0.077	0–0.19	17,22,31,37,54,55,58,74,90,115,116,154,159,170
facial weakness (HB Grades I–IV)	3515	0.048	0.04–0.06	4,11,17,22,24,27,37,44,54,55,58,66,74,80,85,86,90,115,116,119,132,134,143,154,157,159,168,170
facial numbness	4088	0.092	0.02–0.14	3,4,11,17,22,24,25,27,31,44,54–56,63,67,74,77–80,86,90,99,107,116,119,132,134,141,143,154,159,168,170
vertigo, unsteadiness	1919	0.057	0.055–0.059	3,4,58,67,79,86,141,154,159
tinnitus	1919	0.015	0.014–0.016	27,56,154
hydrocephalus requiring shunt	1919	0.040	0.016–0.058	3,17,27,54,56,67,86,109
other§	1919	0.022	NC	3,17,62,67,74,77,80,151,170
recurrence requiring treatment (05 yrs)	6044	0.035	0.023–0.046	3,4,11,17,18,24,25,27,31,37,41,42,44,54–56,58,63,65–67,74,77,80,82,84–86,89,90,95,97,99,107,109,115,116,119,131,137,141,143,149,151,154,157,159,168–170
likelihood that later treatment is microsurgery	273	0.773	NC	
tumor-related deaths	2672	0.010	0.003–0.013	3,4,17,18,22,24,27,37,41,44,54,63,65,66,74,77,86,95,108,109,115,132,143,154,157,159,168–170

* HB = House-Brackmann; NC = not calculated.

† Other complications for the wait-and-see strategy include the following: chronic severe headache and facial paresthesias.

‡ Other complications for microsurgical treatment include the following: CSF leak (with or without repair), bacterial or chemical meningitis, and chronic severe headache.

§ Other complications for radiosurgical treatment include the following: permanent facial spasms, facial and scalp pain, severe chronic headache, persistent nausea and vomiting, dysarthria, and dysphagia.

mates of QOL associated with using each of the 3 management strategies using the decision tree pictured in Fig. 3. One challenge involved estimating and calculating the effects of patients with multiple complications. By convention, QOL is scored proportionately between 1 (perfect health) and 0 (dead).⁴⁹ Without exception, series enumer-

ated complications separately. None reported how many patients suffered multiple complications or which combinations occurred. However, the patient with several complications in addition to loss of useful hearing is likely to have a lower QOL than one in whom hearing loss is an




FIG. 2. Diagram summarizing the literature search. Note that the total number of articles in the 3 categories included in this report is more than 113, as some articles dealt with more than 1 treatment strategy.

regarding the likelihood of multiple complications, we treat most a single complication. The second model considered as many complications as possible to be multiple. Since consensus is to weight individual complications less if they are combined than if each is isolated,⁴⁹ it is likely that the third model overestimates their impact on QOL. The third model and the one used, treats half the complications as single and the other half as multiple. This is discussed in detail in the *Appendix*.

We performed sensitivity analysis for each parameter of the model within its 95% CI to determine its relative importance. We used a 2D Monte Carlo simulation³² (expected value

for 1000 simulated trials, each made up of 1000 micro-simulations). We used beta distributions for all probabilities

C" ĩpcn" ejgm" qh" qwt" tguwnvu" wugf" gzvgtpcn" xcnkfc-tion. Postoperative QOL was measured in several surgi-cal series, using the SF-36,¹⁶³ considered by many to be a reasonable metric for health-related QOL. We compared our calculated postsurgical QOL with a pooled value obtained from global SF-36 scores obtained from the literature.^{9,13,34,71,75,93,96,100,113,153,156,163} The individual domain scores of each study were converted to composite physical and mental QOL scores using an online calculator (<http://www.sf-36.org/>)¹⁶⁴ Ceeugu f" O t e j " : . 4 2 3 2 + . " c p f " v j g " e q o -posite scores were added. In addition, a small number of series reported numbers of patients in whom there were

TABLE 2: Health-related QOL associated with complications*

Complications	No. at Risk	Mean Utility	95% CI	References
no new symptoms	NA	1.0	NA	49
useful hearing loss	1705	0.929	0.89–0.97	8,21,50,52,140,148
facial paralysis (HB Grade VI)	16	0.924	0.88–0.96	33,87
facial weakness (HB Grades I–IV)	36	0.983	0.96–10.0	33,87
facial numbness	156	0.960	0.96–0.96	142
facial spasm	131	0.958	0.94–0.98	59,124,150
facial pain, headache	928	0.935	0.90–0.97	125,127,166
vertigo, unsteadiness	456	0.890	0.87–0.91	1,38,91,92,110
tinnitus	879	0.957	0.91–1.0	7,110,114
hydrocephalus requiring shunt	115	0.965	0.90–1.0	46,83
meningitis	360	0.930	0.93–0.93	117,118
tumor-related death	NA	0.0	NA	49

* NA = not appropriate.

no complications. We compared the prevalence calculated by our model with reported values.

Data from multiple case series were pooled to calculate values for the means and 95% CIs using the random effects model of the metan function in Stata 9 (Stata Corp). For studies in which prevalence varied with time of follow-up, we used Stata 9's metareg function to determine

Tguwnvu

Pooled data from more than 71,000 cases in these 113 reports were used to create evidence tables, from which we calculated the incidence of complications and the recurrence and relative risks for the 3 management strategies. We abstracted estimates of the probabilities of tumor-related death, complications, and recurrence associated with each strategy (Table 1). For example, the 5-year rate of hearing loss is 53% with wait and scan, 44% with microsurgery, and 28% with radiosurgery. These probabilities represent the likelihood that a hypothetical patient travels along a particular pathway pictured in Fig. 3. The reported point estimates of pooled data represent variance-weighted means and were tested to exclude heterogeneity.⁷⁶

The same procedures were followed to assign point estimates for expected QOL associated with each potential complication, and the results are reported in Table 2. Each management strategy was associated with different potential complications in different frequencies. For each strategy, we modeled an average risk of complications

based on the reported frequencies and an average associated QOL.

Rates that were expected to increase over time, such as complications or tumor recurrence, were tested by meta-regression.¹⁵⁵ Variance-weighted rates were regressed against mean duration of follow-up of each series, and pooled values were calculated.

The incidence of each of the complications listed in Table 1 (for example, useful hearing loss, facial weakness, vertigo, and so on) was determined at 5 years using meta-regression analysis. Between the 3 treatment strategies (wait and scan, microsurgery, and radiosurgery) there ygtg"pq"uki pk l ecpv" fkhhtgtpegu"kp"vjg" kpekfgpeg"qh" gcej" complication at 5 years with 1 exception. The only vari- cdng" ykvj" c" uvcvkuvkecn{" uki pk l ecpv" vg o rqtcn" vtgpf" *r">" 0.05) was tumor recurrence rates in the radiosurgery and the wait-and-scan groups compared with microsurgery. The tumor recurrence rate after radiosurgery is illustrated in Fig. 4.

Based on the results of second-order Monte Carlo simulation, health-related QOL at 5 years of follow-up is significantly higher for patients undergoing laparoscopic surgery. Both approaches are superior to the wait-and-scan approach, which is the least favorable option. The results are illustrated in Table 3, which also shows outcomes at 10-year follow-up. Here, there is a trend for higher QOL with microsurgery than with radiosurgery, but the difference is not statistically significant. The results of the second-order Monte Carlo simulation are shown in Figure 3.

Sensitivity analysis supported the results of the Monte Carlo analysis. The model we used gave results that were between 1% and 5% from them. One-way sensitivity analysis suggested the only parameter whose value might alter the choice of strategies was the complication rate of radiosurgery. When plotted against surgical complication rate in a 2-way sensitivity analysis of 5-year outcome, the decision in favor of radiosurgery is shown to be robust (Fig. 5).

Fkewuukqp

Vjku"uwvf{"ku"vjg"t"tuv"swcpvkvcxg"cpf"eqo r t g j g p u k x g" decision analysis for treatment of VS. We established a base case as a patient with a schwannoma less than 2.5 cm in diameter and some useful residual hearing. The base case facilitates the comparisons within the decision analytical model. In practice, however, the treatment decision for VS is highly individualized according to patient/physician preferences and many clinical variables. Nevertheless, the base case is a common and relevant clinical scenario.

Wait-and-Scan Strategy

The wait-and-scan treatment strategy is generally used in patients in whom the tumor is minimally symptomatic because of its small size, or the patient is of advanced age. In a recent meta-analytical retrospective review, Smouha et al.¹³⁹ found that the average tumor size for this strategy was 11.8 mm. The average follow-up in the studies examined




Fig. 3. Decision tree for comparison of outcomes. The 3 management strategies are shown, as are the possible pathways taken by a simulated patient after treatment. Each pathway has a calculated probability and is associated with a calculated outcome.

was 3.2 years and during this time, 57% (709 of 1244) of patients showed no tumor growth. Hearing loss occurred in 51% of patients, and the wait-and-scan strategy failed in 20%, who elected to have further treatment.

Our study reached similar conclusions about conservative management for VSs. By 5 years, hearing loss occurred in 53% of patients, and 24% of patients required additional treatment. Of those requiring additional treatment, 5% of patients who elected to have further treatment contradicts one of the initial rationales for using conservative management, namely that increased age or comorbidities increase the risk of surgical treatment. It is likely that by using a wait-and-scan strategy, the tumor progresses in size such that the window of opportunity for radiosurgery or microsurgery may be lost before the patient's symptoms

necessitate treatment. Therefore, earlier radiosurgery may be optimal for those tumors that demonstrate radiographic growth in the wait-and-scan strategy.

One of the high percentages of patients who lose hearing in the wait-and-scan strategy is the high percentage of patients who lose hearing in the wait-and-scan strategy. Hearing loss is preferable to the complications related to surgical treatment or radiotherapy. However, the overall negative impact on QOL for hearing loss is greater than facial weakness, numbness, spasm, pain, tinnitus, or even hydrocephalus (Table 2). Hearing loss should not be considered an acceptable morbidity in the management of VS, and its impact on an individual should be discussed prior to choosing a treatment strategy.

The wait-and-scan strategy was shown to have the



FIG. 4. Bubble diagram of meta-regression of tumor recurrence rate over time in the radiosurgery group. Each bubble represents 1 of the 50 case series reported. The center of each bubble is located at the mean length of follow-up for the series (x axis) and the reported recurrence rate (y axis). The size of the bubble is proportional to the number of cases reported in the series. The pooled mean incidence over time (solid line) is shown as well as 95% CIs in gray.

lowest QOL compared with radiosurgery and microsurgery at 5- and 10-year follow-up. The predominant reason for the lower QOL was the incidence of functional hearing loss, tinnitus, and vertigo than either microsurgery or radiosurgery. The complications of this treatment strategy are perceived by patients as being more detrimental to QOL than any other treatment-related complication, such as facial weakness. In addition, for those patients who require later treatment, delaying microsurgery or radiosurgery may decrease the chances of success and increase the likelihood of complications.

Microsurgery for VS

Microsurgery for VS has been considered the gold standard of treatment. With improved techniques and neuromonitoring, vestibulocochlear and facial nerve preservation have become the measure of surgical success. Mortality from this procedure has been reported as less than 1% with a greater than 90% chance of preserved facial nerve function.^{12,15,51} Despite these successes, the morbidity of

TABLE 3: Health-related QOL after treatment of VS

Management Strategy	Mean QOL	95% CI	p Value*
5-yr follow-up			
radiosurgery	0.9699	0.9626–0.9772	0.0052
microsurgery	0.9526	0.9430–0.9622	NC
wait & scan	0.8978	0.8949–0.9007	<0.001
10-yr follow-up			
radiosurgery	0.9284	0.8929–0.9639	0.354
microsurgery	0.9515	0.9147–0.9883	NC
wait & scan	0.7825	0.7609–0.8041	<0.001

* Comparisons are made with microsurgery.




FIG. 5. Two-way sensitivity analysis comparing the 3 treatment options as both radiosurgery and microsurgery complication rates are varied. Each zone is labeled by the treatment that yields the best results for that combination of complication rates. The x and y axes represent the ranges of complication rates encompassed by the 95% CIs of the 2 parameters, and the dot in the center of the graph is the combination of the pooled mean rates from the literature. Radiosurgery is the best option for all combinations except very high radiosurgery and low microsurgery complication rates. Wait and scan is never the best strategy.

investigated the rate of long-term hearing preservation in patients after microsurgery for VS and the factors contributing to hearing preservation, even despite the presence of an experienced surgeon and the use of neuromonitoring, only 20% of patients retained functional hearing. Tinnitus occurred in 51% of patients and dizziness in 31% of patients. Raut et al.¹²³ showed a correlation between the size of the schwannoma and preservation of functional hearing, with a 52% chance of preserved hearing if the tumor was less than 2 cm and 83% if the lesion was less than 1 cm.

In this study, based on 1537 combined patients, 44.5% suffered loss of functional hearing after microsurgery. However, our rates of facial weakness (14%) and facial paralysis (8%) are far higher than those reported by some authors such as Betchen et al.¹²⁴ Our rates are higher than the rate seen in certain centers, they represent the average complication rates reported in the literature.

Complete facial paralysis was associated with a negative impact on QOL, and compared with other possible complications, only vertigo was perceived as worse by patients. However, facial weakness without paralysis was not considered to impact QOL to a great extent when compared with other complications (Table 2). Our study found an equivalent rate of facial paralysis following either microsurgical (8%) or radiosurgical (7.7%) treatment of VS, but microsurgery had a greater incidence of facial weakness than that for microsurgery. However, the higher rate of facial weakness after microsurgery does not greatly

chhgev"vjku"l p f k p i . " u k p e g " v j g " p g i c v k x g " k o r c e v " q p " S Q N " h q t " facial weakness is relatively minor.

Similarly, the higher QOL associated with radiosurgery {"qxgt" o ketquwtigt {"ku"pqv"uki pk l e c p v n {" t g n c v g f " v q " v j g " likelihood of tumor recurrence requiring treatment at 5 years. The rate of tumor recurrence was lowest with metquwtigt {"*409 " + . " d w v " k v " f k f " p q v " f k h h g t " u k i p k l e c p v n {" h t q o " the 5-year recurrence rate of radiosurgery (3.5%). In both cases, the treatment of the recurrence was resection in approximately 80% of cases. Therefore, it is the complication "urgek l e " v q " o ketquwtigt {" v j c v " u k i p k l e c p v n {" f g e t g c u g " the QOL at 5 years compared with radiosurgery. These complications include CSF leak and bacterial or chemical meningitis. The negative impact of meningitis on QOL was approximately equal to that of functional hearing loss.

Stereotactic Radiosurgery

Qpg"qh"vjg" o quv"kp l e w g p v k n " u v w f k g u " u w r r q t v k p i " v j g " w u g " of radiosurgery for treatment of VS was written by Pollock et al.¹²² In a prospective study of 82 patients with VSs less than 3 cm, Pollock investigated the outcome at the 42-month follow-up of microsurgery versus radiosurgery. The study found that patients treated with radiosurgery were more likely to maintain normal facial movement and functional hearing than those treated with microsurgery. Vjg" u w t i k e c n " c t o " q h " v j g " u w f {" " j c f " u k i p k l e c p v n {" " y q t u g " scores on physical functioning, energy/fatigue, and pain. Lastly, there was no difference in tumor control. Pollock et al. noted that 14% (30 of 208) of VS treated with radio-uwtigt {" u j q y g f " c " u k i p k l e c p v " i t q y v j " * @ " 4 " o o + " Q h " v j q u g " that increased in size, 20% caused new symptoms, but only 14% required additional treatment.

The results from our study demonstrate a higher rate of complications and recurrence than that reported by Pollock et al.¹²² Combining facial paralysis (7.7%) and facial weakness (4.8%) after radiosurgery, we found that normal facial movement was preserved in 87.5% of cases compared with 96% of cases in Pollock et al. Facial numbness occurred in 9% of radiosurgery cases compared with only 2% of those reported by Pollock et al. However, functional hearing was preserved in 72% of cases in our study versus only 63%. The difference between our study and the published results may be due to modern use of lower marginal doses than in the past. In both studies, the rate of tumor recurrence requiring treatment was approximately 4%. When compared with the other treatment strategies, radiosurgery had a higher incidence of facial numbness (9.2 vs 1.6% for wait and scan) and hydrocephalus requiring a shunt (4 vs 0.4% for microsurgery). Both of these complications are moderate in regard to their negative impact on QOL.

Comparison with Prior Studies and Current Limitations

Gzvgtpcn" g x k f g p e g " c n u q " r t q x k f g u " u w r r q t v " h q t " q w t " l p f - ings. We found 12 case series reporting QOL in a total of 967 patients undergoing microsurgical treatment of VS, as measured by SF-36 scores. The pooled mean QOL was 0.952. Our model calculated an average QOL of 0.953. In addition, Kondziolka et al.⁸¹ reported that 69% of 115 patients were complication free between 5 and 10 years after

radiosurgery. Our model calculated the number to be 71% at 5 years. One series in the wait-and-scan category reported that 44.9% of its 49 patients developed neither new nor worsened symptoms during a mean follow-up of 3 years.¹⁰³ Our model calculated this number to be 44.5% at 5 years.

The literature contains a previous decision analysis on treatment of VS.⁶⁴ This study, while reaching the same conclusions about the superiority of radiosurgery over microsurgery, lacked a number of features critical to o q f g t p " f g e k u k q p " c p c n { u g u l " Q w v e q o g u " y g t g " p q v " s w c p v k l g f . " making statistical comparisons and sensitivity analysis impossible. The diverse effect of time on the 2 groups in terms of recurrence and complication incidence was i g - p q t g f 0 " E q o r n k e c v k q p " c p r " o q t v c n k v { " t c v g u " t g E g e v " f c v c " h t q o " an earlier time period and are higher than in more recent reports. The present study is based on a more complex model with longer follow-up data.

Our study shares the potential drawbacks of all such decision analytical models. We made several simplifying assumptions, any of which may impact our results. The calculated values for microsurgery and radiosurgery are close to those of perfect health, and the differences between v y g g p " v j g o " s w k v g " u o c n n l " C " o q f g u v " e j c p i g " k p " v j g " o q f g n u " assumptions might alter our conclusions. For example, we cannot be certain that our handling of multiple complications is accurate, although the external evidence tends to validate our choice. In addition, the SF-36 has been criticized as a measure of QOL in cases of VS, as well as other contexts.⁴⁰ We cannot dispute this assertion but eqw n f " p q v " l p f " c p " c n v g t p c v k x g " o g v t k e " k p " v j g " n k v g t c v w t g l

The fact that surgical complications tend to present immediately, whereas complications of radiosurgery and conservative management are delayed makes comparisons f k h l e w n l " Y g " j c x g " w u g f " o g v c / t g i t g u k q p " v q " j g n r " w u " q x g t - come this obstacle. Intuition suggests that information on individual patients, which is rarely reported in case series, is needed to document appearance of delayed complications. However, for binary data such as recurrence and mortality, case numbers and mean follow-up duration are adequate. Our regression assumes that delayed complication " c e e t w g " k p " c " n k p g c t " h c u j k q p l " C n v j q w i j " v j k u " k u " e g t v c k p n { " c p " q x g t u k o r n k l e c v k q p . " u g p u k v k x v { " c p c n { u k u " c p f " g z v g t p c n " g x k - f g p e g " u w i i g u v " v j c v " v j k u " f q g u " p q v " k p x c n k f c v g " q w t " l p f k p i u l

Long-term follow-up studies are so sparse that data uncertainties accumulate as the model approaches 10 years. C n v j q w i j " v j g t g " k u " c " o w e j " i t g c v g t " f k h h g t p e g " d g v y g g p " q w v - comes in the micro- and radiosurgical groups at 10 years than at 5, the 95% CIs are so wide that this difference is no n p p i g t " u k i p k l e c p v l " H k i w t g " 6 " k u " c p " g z c o r n g " q h " v j k u " i t q y k p i " data uncertainty. The mean 10-year recurrence rate after radiosurgery is calculated at 8%, but the 95% CI is anywhere between 5 and 11%. Until more late-term data are collected, we cannot determine whether the apparent advantage of microsurgery over radiosurgery is valid.

Finally, we concede that a decision analysis cannot t g r n c e g " c " y g n n / e q p v t q n n g f . " t c p f q o k l g f " v t k n l " C v " d g u v . " k v " e c p " only approximate the outcome of such a trial. However, if our approximation is close to correct, it is extremely unlikely that the required trial is practical. For an expected difference in the primary end point (QOL) of 1–2% and u w c p f c t f " u v c v k u v k e c n " t g s w k t g o g p v u " h q t " u k i p k l e c p e g " * r q y g t "

qh" :2 ' .4/vckngf"v/vguv."cpf"r">"2027+."c"uc o rng"uk |g"qh"
more than 6700 cases would be needed for each group.

Eqpenwukqpu

Cv"7" {gctu."rcvkpgvu"vtgcvgf" ykvj" tcfkquwtigt{"jcxg"
an overall better QOL than those treated with either microsurgery or those who undergo follow-up with serial imaging. Patients found that the complications associated with the wait-and-scan and microsurgery treatment strategies impacted their QOL more than the complications from radiosurgery. One limitation of this study is that the 10-year follow-up data were too limited to demonstrate yjgvjgt" c"uki pk fcepv" fkhhtgtpgpeg"gzkuvgf"dgvyggp"vjg"tc-diosurgery and microsurgery groups.

Crrgpfkz"Ecnewncvpi" Wvknkvgu"kp"Rcvkpgvu ykvj"Rquv/Vtgcvo gpr"Eq o rkecvkqpu

Cu"o gpvkpggf"cdxg."rwdnku jgf"ugtgu"jcxg"pqv"tgrqtvf"kp"y jcv"
proportion of patients treatment complications are multiple, and they have not detailed which complications tend to occur together. We approached this obstacle by calculating overall complication rates and utilities using 3 separate theoretical models and choosing the one that resulted in outcomes that approximated most closely those in the literature.

For the purposes of illustration, we use 3 complications in an gzc o rng"cpf"cr rn{"cm"5" o qfgnu"Cu"ecp"dg"uggp"kp"Vcdng"6."eq o rnk-ecvkqp"C"ku"vjg" o quv"eq o o qp."qewttkpi"kp"52 " "qh"ecugul"Kv"ku"cnug" the most serious, being associated with a utility of 0.7 (normal health ecttkgu" c"vknkv{"qh"3+0" Oqfgn"C"vtgcvu"vjg"eq o rkecvkqpu"cu" o wvwnm{" exclusive; a patient can have at most 1 complication. Model B treats the complications as maximally multiple. Thus, 10% of patients have cm"5."32 " "jcxg"eq o rkecvkqpu"C"cpf"D."cpf"32 " "jcxg"eq o rkecvkqp" C"cnqpg" Oqfgn"E"ku"kpvtg o gfkcyg"cpf"vtgcvu"qpg/jcnh"qh"vjg"rcvkpgvu" vjg"uc o g"cu" Oqfgn"C"cpf"vjg"qvjgt" jcnh"cu" Oqfgn"D" Vjgug"ctg" illustrated in Fig. 6. Utilities of patients with multiple complications o wvknr{"0"Hqt"gzc o rng."c"rcvkpgv" ykvj"dqvj"eq o rkecvkqpu"C"cpf"D" has a utility of 0.7 X 0.8, or 0.56.

Vcdng"7" tgrqtvu"vjg"qvwrvvu"qh"cm"5" o qfgnu"Cu" fkuwugf"kp"
Methods. Oqfgn"C"vgpfu"vq"qxgtg o rjcuk|g"vjg"ghhgev"qh" o wvknrg" complications on outcome, and Model B tends to do the opposite. Model C, which is what we used in our final calculations, yields kpgt o gfkcyg" tguwvnu"Cu" o gpvkpggf"kp"*Results,* the model predicted overall QOL and complication-free rates quite accurately, and published results tend to support its validity.

TABLE 4: Complication rates and utilities

Complication	Frequency	Associated Utility
A	0.3	0.7
B	0.2	0.8
C	0.1	0.9

Fkueqwtg

TABLE 5: Calculated total complication rates and utilities

Model	Total Complication Rate (%)	Mean Utility
A	60	0.860
B	30	0.876
C	45	0.868




FIG. 6. Subtrees for calculating complication rates and utilities in the example. Panels A, B, and C represent the subtrees for Models A, B, and C, respectively. The p_A, p_B, p_C and u_A, u_B, u_C represent the probabilities and utilities associated with complications A, B, and C, respectively.

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Cwjqteqpvtdwvqpu"vq"vjg"uwvf{"cpf"ocpwuetkrv"rtgrctckqp" include the following. Conception and design: JYK Lee, SC Stein. Ceswkvkqp"qh"fcvc<"E"Wtdcp."G"Ejwtej."UE"Uvgkp" Cpcn{uku"cpf" interpretation of data: RG Whitmore, SC Stein. Drafting the article: RG Whitmore, SC Stein. Critically revising the article: JYK Lee, RG Whitmore, M Ruckenstein, SC Stein. Reviewed final version of the manuscript and approved it for submission: JYK Lee, RG Whitmore, C Urban, E Church, M Ruckenstein, SC Stein. Statistical analysis: UE"Uvgkp" Cf o kpkuvtkxglvgejpkecn o cvgtkcn uwrrqtvc" L [M" Ngg." UE" Stein. Study supervision: JYK Lee, SC Stein.

Tghgtgegu"

- " 30" Cdgng"O."Maqemigvjgt"V<"Jgcuvj/tgncvgf"swcnkv{"qh"nkhg"kp"urq-radic adult-onset ataxia. **Oqx"Fuqtf 22**:348–352, 2007
- " 40" Cpcpf"XV."Mgtt"CI."D{tpgu"FR"Uo{vj" IF<"Pqp/uwtikecn" management of acoustic neuromas. **Enkp"Qvqnet{piqn" Cmkgf" Uek 17**:406–410, 1992
- " 50" Cpfgyu"FY."Uknxgt ocp"EN." Incuu" L." Fqypgu" D." Tkng{" TL." Corn BW, et al: Preservation of cranial nerve function after treatment of acoustic neurinomas with fractionated stereotactic radiotherapy. Preliminary observations in 26 patients. **Uvgqvcev" Hwpev" Pgwqtqwti 64**:165–182, 1995
- " 60" Cpfgyu"FY."Uwctgl"Q." Iqnf ocp" J Y." Fqypgu" OD." Dgfpc" G, Corn BW, et al: Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: comparative observations of 125 patients treated at one institution. **Kpv" L" Tcfkcv" Qpeqn" Dkqn" Rj {u 50**:1265–1278, 2001
- " 70" Cttkic"OC."Ejgp"FC<"Uwtikecn"vtgcv o gpv"qh"wpq o rgpucvgf" vestibular disease. **Qvqnet{piqn" Enkp" Pqtvj" C o 30**:759–776, 1997
- " 80" Cttkic"OC."Ejgp"FC."Hmwujko c"V<"Kpfkxkfwcn|kpi" jgct-ing preservation in acoustic neuroma surgery. **Nct{piqueqrg 107**:1043–1047, 1997
- " 90" C{fgokt" I." Vg|gt" OU." Dqt ocp" R" Dqfw" J." Wpcn" C<" Vtgc-vment of tinnitus with transcutaneous electrical nerve stimulation improves patients' quality of life. **L" Nct{piqn" Qvqn 120**: 442–445, 2006
- " :0" Dctvqp" IT." Depmctv" L." Fcxku" CE<" C" eq o rctkuqp" qh" vjg" swcnkv" of life of hearing-impaired people as estimated by three different utility measures. **Kpv" L" Cwfkqn 44**:157–163, 2005
9. Baumann I, Polligkeit J, Blumenstock G, Mauz PS, Zalaman IM, Maassen MM: Quality of life after unilateral acoustic neuroma surgery via middle cranial fossa approach. **Cevc" Qvqnet{piqn 125**:585–591, 2005
- 320" Dgfgtuqp" LD." xqp" C o oqp" M." Ykej ocpp" Y Y." [c ctiqn" O I<" Conservative treatment of patients with acoustic tumors. **Neu/ tquwtigt{ 28**:646–651, 1991
- 330" Dgging" TF." Htkgf ocp" YC." Dqxc" HL<" Ghghev" qh" vtgcv o gpv" rncp" quality on outcomes after radiosurgery for vestibular schwannoma. **J Neurosurg 107**:913–916, 2007
- 340" Dgvejgp" UC." Ycnuj" L." Rquv" MF<" Nqpi/vgt o" jgctkpi" rtgugtxc-tion after surgery for vestibular schwannoma. **J Neurosurg 102**:6–9, 2005
- 350" Dgvejgp" UC." Ycnuj" L." Rquv" MF<" Ugnh/cuuguugf" swcnkv{"qh"nkhg"ch-ter acoustic neuroma surgery. **J Neurosurg 99**:818–823, 2003
- 360" Dq|qti" I tc{gnk" C." Mcnc o ctkfgu" O." Hgttct" G." Dqweect" F." Gn" I jctgo" J." Tg{ " C." gv" cnk" Eqpugtxcvkg" o cpcig o gpv" xgtuwu" surgery for small vestibular schwannomas. **Cevc" Qvqnet{piqn 125**:1063–1068, 2005
- 370" Dtki iu" TL." Hcdkp{ k" I." Mc{g" C J<" Ewttgpv" o cpcig o gpv" qh" ceqwu-tic neuromas: review of surgical approaches and outcomes. **J Enkp" Pgwqtqek 7**:521–526, 2000
- 380" Ectfquq" CE." Hgtpepfgu" [D." Tc o kpc" T." Dqtigu" I<" Ceqwuvke" neuroma (vestibular schwannoma): surgical results on 240 patients operated on dorsal decubitus position. **Cts" Pgwqtq/ rukskewt 65 (3A)**:605–609, 2007
- 390" Ejcp" CY." Dncem" R." Qlg o ccpp" T I." Dctmgt" H I " Kk." Mqq{ " J O." Nrgu" VV, et al: Stereotactic radiotherapy for vestibular schwannomas: favorable outcome with minimal toxicity. **Pgwqtqwtigt{ 57**:60–70, 2005
- 3:0" Ejcpj" UF." I kddu" KE." Ucm o qvq" I V." Ngg" G." Q{ gngug" C." C fngt" JR Jr: Staged stereotactic irradiation for acoustic neuroma. **Pgwqtqwtigt{ 56**:1254–1263, 2005
19. Charabi S, Tos M, Thomsen J, Charabi B, Mantoni M: Ves-tibular schwannoma growth—long-term results. **Cevc" Qvqnet/ {piqn" Uwrn 543**:7–10, 2000
20. Charabi S, Tos M, Thomsen J, Rygaard J, Fundova P, Charabi B: Cystic vestibular schwannoma—clinical and experimental studies. **Cevc" Qvqnet{piqn" Uwrn 543**:11–13, 2000
21. Chia EM, Wang JJ, Rochchina E, Cumming RR, Newall P, Mitchell P: Hearing impairment and health-related quality of life: the Blue Mountains Hearing Study. **Gct" Jget 28**:187–195, 2007
22. Chihara Y, Ito K, Sugawara K, Shin M: Neurological complica-tions after acoustic neurinoma radiosurgery: revised risk fac-tors based on long-term follow-up. **Cevc" Qvqnet{piqn" Uwrn 559**:65–70, 2007
23. Chopra R, Fergie N, Mehta D, Liew L: The middle cranial fossa approach: an anatomical study. **Uwti" Tcfkqn" Cpcv 24**: 348–353, 2003
- 460" Ejqrte" T." Mqpf |kqnm" F." Pkteclpc" C." Nwpuhqtf" NF." Hnkem-inger JC: Long-term follow-up of acoustic schwannoma ra-diosurgery with marginal tumor doses of 12 to 13 Gy. **Kpv" L" Tcfkcv" Qpeqn" Dkqn" Rj {u 68**:845–851, 2007
25. Chung HT, Ma R, Toyota B, Clark B, Robar J, McKenzie M: Cwfkqnike" cpf" vtgcv o gpv" qweq o gu" chvg" nkgct" ceeggtcvqt/ based stereotactic irradiation for acoustic neuroma. **Kpv" L" Tc/ fkc" Qpeqn" Dkqn" Rj {u 59**:1116–1121, 2004
- 480" Ejwpi" UL." K o" L J." Ngg" L J." Ejq" C J." Myqp" O." Ngg" OE<" Kuqncv-ed tongue tremor after gamma knife radiosurgery for acoustic schwannoma. **Oqx" Fuqtf 20**:108–111, 2005
27. Chung WY, Liu KD, Shiao CY, Wu HM, Wang LW, Guo WY, et al: Gamma knife surgery for vestibular schwannoma: 10-year experience of 195 cases. **J Neurosurg 102 Uwrn**:87–96, 2005
28. Cohen NL, Lewis WS, Ransohoff J: Hearing preservation in cerebellopontine angle tumor surgery: the NYU experience 1974–1991. **C o" L" Qvqn 14**:423–433, 1993
29. Colletti V, Fiorino F, Mocella S, Carner M, Policante Z: "En-bloc" removal of small- to medium-sized acoustic neuromas with retrosigmoid-transmeatal approach. **Umwml" Dcug" Uwti 7**: 31–38, 1997
30. Colletti V, Fiorino F, Policante Z, Bruni L: Intraoperative monitoring of facial nerve antidromic potentials during acous-tic neuroma surgery. **Cevc" Qvqnet{piqn 117**:663–669, 1997
31. Combs SE, Thilmann C, Debus J, Schulz-Ertner D: Long-term outcome of stereotactic radiosurgery (SRS) in patients with acoustic neuromas. **Kpv" L" Tcfkcv" Qpeqn" Dkqn" Rj {u 64**:1341–1347, 2006
- 540" Eqpecvq" L." Hgkpuvgkp" CT<" Oqpvg" Ectnq" o gvjqfu" kp" enkpkecn" tg-search: applications in multivariable analysis. **L" kpxguvki" Ogf 45**:394–400, 1997
- 550" Eqwuuq" UG." Qify {gt" PL." Cfc o u" TF." Etquzqp" I T<" Gzrtgu-sion of emotion and quality of life after facial nerve paralysis. **Qvqn" Pgwqtqvn 25**:1014–1019, 2004
- 560" fc" Etw| " OL." Oqhhev" FC." J ctf{ " F I<" Rquvrgtgcxg" swcnkv{"qh" life in vestibular schwannoma patients measured by the SF36 Health Questionnaire. **Nct{piqueqrg 110**:151–155, 2000
35. Darrouzet V, Martel J, Enée V, Bébér JP, Guérin J: Vestibular schwannoma surgery outcomes: our multidisciplinary experi-ence in 400 cases over 17 years. **Nct{piqueqrg 114**:681–688, 2004

36. Deen HG, Ebersold MJ, Harner SG, Beatty CW, Marion MS, Wharen RE, et al: Conservative management of acoustic neuroma: an outcome study. **Pgwtqwtigt{ 39:260–266, 1996**
37. Delbrouck C, Hassid S, Massager N, Choufani G, David P, Devriendt D, et al: Preservation of hearing in vestibular schwannomas treated by radiosurgery using Leksell Gamma Knife: preliminary report of a prospective Belgian clinical study. **Cevc"Qvqtjbpqnet{piqnDgni 57:197–204, 2003**
- 5:0" fw"Oqpvegn"UV."Ejctngu"R."Tkdc"R."I qk|gv"E."Ng"De"qp"C."Nc-bauge P, et al: Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. **Dtclp 131:1352–1361, 2008**
- 5:0" Gn/Mcu jncp"J M." \ gkvqwp"J."Ctvu"J C."J qhh"LV."Vgnkcp"UC"TG-currence of acoustic neuroma after incomplete resection. **C o" L"Qvqn 43:389–392, 2000**
40. Farace E, Marshall LF: Quality of life in acoustics. **J Neuro/surg 99:807–809, 2003**
41. Flickinger JC, Kondziolka D, Lunsford L: Fractionation of radiation treatment in acoustics. Rationale and evidence in comparison to radiosurgery. **Pgwtqejktwtik 50:421–426, 2004**
- 640" Hnkemkpi gt"LE."Mqpf |kqnm" F."Pkteplep"C."Ockv| "C."Xq{pqx" I." Nwpuhqt"NF<"Cequwvke"pgwtqo c"tcfkqwtigt{" ykvj"o ctikpcn" tumor doses of 12 to 13 Gy. **kpv" L" Tcfkcv" Qpeqn" Dkqn" Rj {u 60:225–230, 2004**
- 650" Hnkpv" F."Hci cp"R."Repctgug" C<"Eqpugtxcvkxg" o cpcig o gpv"qh" sporadic unilateral acoustic neuromas. **L"Nct{piqn"Qvqn 119: 424–428, 2005**
- 660" Htkgf o cp"YC."Dtcfujcy"R."O {gtu"C."Dqxc"HL" Nkpgct"ceegn-erator radiosurgery for vestibular schwannomas. **J Neurosurg 105:657–661, 2006**
- 670" Hweek"OL."Dwej o cp"EC."Dtcem o cpp"FG."Dgntkpgt"MK<"Cequw-utic tumor growth: implications for treatment choices. **C o" L" Qvqn 20:495–499, 1999**
- 680" I gmkpi"N."Kffqp" L."OeXlect" C."Rkcmctf"LF<"EUH"ektewncvkqp" disorders: measuring progress in patients through quality of life and hope. **L"Enkp" Pwtu 13:589–600, 2004**
47. Glasscock ME III, Pappas DG Jr, Manolidis S, Von Doersten PG, Jackson CG, Storper IS: Management of acoustic neuroma in the elderly population. **C o" L"Qvqn 18:236–242, 1997**
- 6:0" I 3muw" P." [kn o c| " O." De"tc o qinw" K." C{ fkn" W." De" c| kv" [C<" Evaluation of the results of endoscope-assisted acoustic neuroma surgery through posterior fossa approach. **QTN" L"Qvq/ t jbpqnet{piqn" Tgncv" Uрге 67:87–91, 2005**
49. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds): **Equv/ Ghhgevkxpggu" kp" J gcnv j" cpf" O gfkcpq** New York: Oxford University Press, 1996
- 720" I twygtu"LR" Lqqtg" O C."xcp"fgt" J qtuw" H."Xgtuej wwtg" J." Ftguejngt" YC."Cpvgwku" NL<"Ejqqkpi" dgvyggp" o gcuwtgu" eq o rctkuq"qh" EQ-5D, HUI2 and HUI3 in persons with hearing complaints. **Swcn" Nkhg" Tgu 16:1439–1449, 2007**
- 730" I wgtkp" E."Uc o rcvj" R."Nqpi" F O<"Cequwvke"pgwtq o c<"qweq o g"qh" surgical resection and study on the anatomy of facial and cochlear nerves. **Cpp" Cef" Ogf" Ukpierqtg 28:402–408, 1999**
52. Hallberg LR, Hallberg U, Kramer SE: Self-reported hearing fkh fawnkgu."eq o owpkecvkqp" uvtcvgi gu" cpf" ru{ejqni kecn" igp-eral well-being (quality of life) in patients with acquired hearing impairment. **Fkuedkn" Tg jcdkn 30:203–212, 2008**
- 750" J ctdqwt" T." Oknngt" L" C" pg y" u{uyg o "hqt" i tcfkpi" tgeq o o gpf-cations in evidence based guidelines. **DOL 323:334–336, 2001**
54. Hasegawa T, Fujitani S, Katsumata S, Kida Y, Yoshimoto M, Koike J: Stereotactic radiosurgery for vestibular schwanno-mas: analysis of 317 patients followed more than 5 years. **Neu/ tqwtigt{ 57:257–265, 2005**
55. Hasegawa T, Kida Y, Kobayashi T, Yoshimoto M, Mori Y, Yoshida J: Long-term outcomes in patients with vestibular schwan-nomas treated using gamma knife surgery: 10-year follow up. **J Neurosurg 102:10–16, 2005**
56. Hasegawa T, Kida Y, Yoshimoto M, Koike J, Goto K: Evalua-tion of tumor expansion after stereotactic radiosurgery in pa-tients harboring vestibular schwannomas. **Pgwtqwtigt{ 58: 1119–1128, 2006**
57. Hecht CS, Honrubia VF, Wiet RJ, Sims HS: Hearing preserva-tion after acoustic neuroma resection with tumor size used as a clinical prognosticator. **Nct{piqueqrg 107:1122–1126, 1997**
- 7:0" J g o rgn" LO." J g o rgn" G." Yqytc" D." Ue jke jqt" Ej." Owcegxe" C." Tkfgtgt" C<" Hwpevkpcn" qweq o g" chvgt" i c o o c" mpkhg" v tgc v o gpv" in vestibular schwannoma. **Gwt" Cte j" Qvqtjbpqnet{piqn 263: 714–718, 2006**
59. Heuser K, Kerty E, Eide PK, Cvancarova M, Dietrichs E: Mi-crovascular decompression for hemifacial spasm: postopera-tive neurologic follow-up and evaluation of life quality. **Eur J Pgwtqn 14:335–340, 2007**
60. Hoistad DL, Melnik G, Mamikoglu B, Battista R, O'Connor EC." Y kv" TL<" Wr fcvq" qp" eqpugtxcvkxg" o cpcig o gpv" qh" cequwvke" neuroma. **Qvqn" Pgwtqvn 22:682–685, 2001**
- 830" J qukpi gt" HE." Eqmgt" PL." Lgpmkpu" J C<" J gctkpi" rtgugtxcvkp" kp" conservation surgery for vestibular schwannoma. **C o" L" Qvqn 21:695–700, 2000**
- 840" J qtu v o cpp" I C." Xcp" Gem" CV<" I c o o c" mpkhg" o qfgn" E" ykvj" the automatic positioning system and its impact on the treat-ment of vestibular schwannomas. **J Neurosurg 97 (5 Uwr r n< 450–455, 2002**
63. Huang CF, Tu HT, Lo HK, Wang KL, Liu WS: Radiosurgery for vestibular schwannomas. **L" E jkp" Ogf" Cuuqe 68:315–320, 2005**
64. Hudgins WR: Patients' attitude about outcomes and the role of gamma knife radiosurgery in the treatment of vestibular schwannomas. **Pgwtqwtigt{ 34:459–465, 1994**
65. Inoue HK: Low-dose radiosurgery for large vestibular schwan-nomas: long-term results of functional preservation. **J Neuro/ surg 102 *Uwr r n< 111–113, 2005**
66. Ishihara H, Saito K, Nishizaki T, Kajiura K, Nomura S, Yoshikawa K, et al: CyberKnife radiosurgery for vestibular schwannoma. **Okpko" Kpxcukxg" Pgwtquwti 47:290–293, 2004**
67. Iwai Y, Yamanaka K, Ishiguro T: Surgery combined with ra-diosurgery of large acoustic neuromas. **Uwti" Pgwtqn 59:283–291, 2003**
- 8:0" Lceqd" C." Tqdkpuqp" NN" Lt." Dqtv o cp" LU." [w" N." Fqfuqp" GG." Welling DB: Nerve of origin, tumor size, hearing preserva-tion, and facial nerve outcomes in 359 vestibular schwannoma resections at a tertiary care academic center. **Nct{piqueqrg 117:2087–2092, 2007**
69. Jain VK, Mehrotra N, Sahu RN, Behari S, Banerji D, Chhabra DK: Surgery of vestibular schwannomas: an institutional ex-perience. **Pgwtqn" Kpfkc 53:41–45, 2005**
70. Jaisinghani VJ, Levine SC, Nussbaum E, Haines S, Lindgren B: Hearing preservation after acoustic neuroma surgery. **Umwmm" Dcug" Uwti 10:141–147, 2000**
- 930" Lgpmkpuqp" E." Eqwnvgt" C." Ytki jv" N<" Ujqtvt hqt o "58"UH58+" j gcnv j" survey questionnaire: normative data for adults of working age. **DOL 306:1437–1440, 1993**
- 940" Lg{cmw o ct" C." Ug v j" T." Dtkem o cp" VO." Fwwejgt" R<" V jg" rtgxc-lence and clinical course of patients with 'incidental' acoustic neuromas. **Cevc" Qvqnet{piqn 127:1051–1057, 2007**
- 950" Lqpgu"UG." Dci wng{ "FO." Oqhkhv" FC<" Ct g" hcekn" pgtxg" qweq o gu" worse following surgery for cystic vestibular schwannoma? **Umwmm" Dcug 17:281–284, 2007**
74. Karpinos M, Teh BS, Zeck O, Carpenter LS, Phan C, Mai WY, et al: Treatment of acoustic neuroma: stereotactic radio-surgery vs. microsurgery. **kpv" L" Tcfkcv" Qpeqn" Dkqn" Rj {u 54: 1410–1421, 2002**
75. Kelleher MO, Fernandes MF, Sim DW, O'Sullivan MG: Health-related quality of life in patients with skull base tu-mours. **Dt" L" Pgwtquwti 16:16–20, 2002**
- 980" Mkpi" LV" Lt." Inkem" J C." Ocuqp" VL." Hnc o o" GU<" Gngevkxg" uwtigt{ " for asymptomatic, unruptured, intracranial aneurysms: a cost-effectiveness analysis. **J Neurosurg 83:403–412, 1995**

- 990" Mqj" GU." Okmct" DC." O²pctf" E." Okejcgnu" J." Jg{fctkcp" O." Ladak S, et al: Fractionated stereotactic radiotherapy for acoustic neuroma: single-institution experience at The Princess Margaret Hospital. **Ecepgt** 109:1203–1210, 2007
- 9:0" Mqpf|kqnm" F." Hktkm" CF." Nwpuhqt" NF<"Eq o rkecvkpu"qh"uvgr-eotactic brain surgery. **Pgwtqn"Enkp** 16:35–54, 1998
- 9:0" Mqpf|kqnm" F." Nwpuhqt" NF<"Cequwvke"pgwtq o cu<"tguwvu"qh"ewt-rent surgical management. **Pgwtqwtigt** 42:1401–1402, 1998
- :20" Mqpf|kqnm" F." Nwpuhqt" NF." Hnkemkpi"gt"LE<"Cequwvke"pgwtq o c" radiosurgery. Origins, contemporary use and future expectations. **Pgwtqejktwtik** 50:427–435, 2004
81. Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC: Long-term outcomes after radiosurgery for acoustic neuromas. **P"Gpin"LOgf"55**;:1426–1433, 1998
82. Kondziolka D, Subach BR, Lunsford LD, Bissonette DJ, Flickinger JC: Outcomes after gamma knife radiosurgery in uqnvct{ "cequwvke"vw o qtu"cpf"pgwtq|dtq o cvquku"V{rg"40"Neu/tqwti"Hqewu 5(3):e2, 1998
- :50" Mwmnctpk" CX." Ftcng" LO." Tcdk" F." Fktmu"RD." Jw o r jtg{u"TR" Rutka JT: Measuring the health status of children with hydrocephalus by using a new outcome measure. **J Neurosurg** 101 (2 Uwrn<141–146, 2004
84. Kwon Y, Kim JH, Lee DJ, Kim CJ, Lee JK, Kwun BD: Gamma knife treatment of acoustic neurinoma. **Uvgtgqvce"HWpev" Neurosurg** 70 *Uwrn<3<57–64, 1998
- :70" Ncpf{ "JL" Octmg" CO." Yw"Z." Rcevjgp"UL." Tgku"KO." Vcmkvc"E." gv"cn<"Uchgv{ "cpf"gh{e{ "qh"vktgf"nk o kvgf/fqug"ic o o c"mpkhg" stereotactic radiosurgery for unilateral acoustic neuroma. **Uvg/tgqvce"HWpev"Pgwtqwti** 82:147–152, 2004
86. Lee GY, Roos DE, Brophy BP: Radiosurgery for vestibular uejycppq o cu<"rtgnk o kpc{ "tguwvu"qh"vjg" Cfgnckfg"gzrgtk-ence. **Uvgtgqvce"HWpev"Pgwtqwti** 76:209–212, 2001
- :90" Ngg" L." Hwpi" M." Nqypkg"UR" Rctpgu"NU" Cuuguupi"ko rckt o gpv" and disability of facial paralysis in patients with vestibular schwannoma. **Ctej"Qvqnet{piqn"Jgcf"Pgem"Uwti** 133:56–60, 2007
88. Levo H, Pyykkö I, Blomstedt G: Non-surgical treatment of vestibular schwannoma patients. **Cevc"Qvqnet{piqn"Uwrn** 529: 56–58, 1997
89. Lin VY, Stewart C, Grebenyuk J, Tsao M, Rowed D, Chen J, et al: Unilateral acoustic neuromas: long-term hearing results in patients managed with fractionated stereotactic radiotherapy, hearing preservation surgery, and expectantly. **Nct{piqueqrg** 115:292–296, 2005
90. Litvack ZN, Norén G, Chougule PB, Zheng Z: Preservation of functional hearing after gamma knife surgery for vestibular schwannoma. **Pgwtqwti"Hqewu** 14(5):e3, 2003
- :30" N>rg|/Dcuwfc" L." Rgtguvgn/R²tg| "N." Oqp>p/Cnxctg| "H." Uggttc-pq/Ci wknct"R<"Uqekc"geqpp o ke"equvu"cpf" jgcw j/tgncvgf" swen-ity of life in patients with degenerative cerebellar ataxia in Spain. **Oqx"Fluqtf** 23:212–217, 2008
- :40" Nqrg|/Guec o g| "LC." I c o k| "OL" Hgtpcpf|/Rgtg| "C." I q o g|/Hk-ñana M, Sanchez-Canet I: Impact of treatment on health-related quality of life in patients with posterior canal benign paroxys-mal positional vertigo. **Qvqn"Pgwtqvqn** 24:637–641, 2003
- :50" OecPpfkg" E." Etqyvjgt"LC<" Swcnkv{ "qh"nkhg" kp" rcvkgpvu" ykvj" vestibular schwannomas managed conservatively. **Enkp"Qvq/nct{piqn" Cmkgf"Uek** 29:215–218, 2004
94. Magnan J, Barbieri M, Mora R, Murphy S, Meller R, Bruzzo M, et al: Retrosigmoid approach for small and medium-sized acoustic neuromas. **Qvqn"Pgwtqvqn** 23:141–145, 2002
- :70" Ocktg"LR" J wejgv" C." Okndgq| "Fcttqw|gv"X." Ecwuug" P." E²-lériér D, et al: Twenty years' experience in the treatment of acoustic neuromas with fractionated radiotherapy: a review of 45 cases. **kp" L" Tcfkcv"Qpeqn"Dkqn"Rj{u** 66:170–178, 2006
96. Martin HC, Sethi J, Lang D, Neil-Dwyer G, Lutman ME, Yardley L: Patient-assessed outcomes after excision of acous-tic neuroma: postoperative symptoms and quality of life. **J Neurosurg** 94:211–216, 2001
97. Massager N, Nissim O, Delbrouck C, Devriendt D, David P, Desmedt F, et al: Role of intracranial volumetric and dosimetric parameters on hearing preservation after vestibular schwannoma radiosurgery. **kp" L" Tcfkcv"Qpeqn"Dkqn"Rj{u** 64: 1331–1340, 2006
98. Massick DD, Welling DB, Dodson EE, Scholfield M, Nagaraja HN, Schmalbrock P, et al: Tumor growth and audiometric change in vestibular schwannomas managed con-servatively. **Nct{piqueqrg** 110:1843–1849, 2000
- " ; :0" OeEngmcpf"U"KKK." I gtdk"DL." J k i kpu"RF." Qtpgt"LD." J cmn"Y C<" Safety and efficacy of fractionated stereotactic radiotherapy for acoustic neuromas. **L"Pgwtqqpeqn** 86:191–194, 2008
100. McDowell I, Jenkinson C: Development standards for health measures. **L"Jgcw j"Ugtx" Tgu"Rqnk** 1:238–246, 1996
101. Mirz F, Jørgensen B, Fiirgaard B, Lundorf E, Pedersen CB: Investigations into the natural history of vestibular schwan-nomas. **Enkp"Qvqnet{piqn" Cmkgf"Uek** 24:13–18, 1999
- 3240" Ok{c|cmk" J." Fgxxg|g" C." Ocipc" L" Pgwtq/qvqnqike" uwtigt{ " through minimally invasive retrosigmoid approach: endo-scope assisted microvascular decompression, vestibular neu-rotomy, and tumor removal. **Nct{piqueqrg** 115:1612–1617, 2005
- 3250" Oqfwipq" I E." Rktqffc" C." Hgttk" I I." Hkqtexcpk" C." Ecndweek" H." Rg|j k" C." gv"cn<"U o cmn"cequwvke"pgwtq o cu<"o qpkvktkpi"vjg"i tq yvj" rate by MRI. **Cevc"Pgwtqejkt"Ykgp+** 141:1063–1067, 1999
- 3260" Oqhncv" FC." fc" Etw| " OL." Dciwng{ " FO." Dg{ppq" IL." Jctf{ " DG: Hearing preservation in solitary vestibular schwannoma surgery using the retrosigmoid approach. **Qvqnet{piqn"Jgcf" Pgem"Uwti** 121:781–788, 1999
- 3270" Oāmg" CT<" Fkcipquku" qh" cequwvke" vw o qtu" C o " L" Qvqn 21: 151–152, 2000
106. Møller P, Myrseth E, Pedersen PH, Larsen JL, Krakenes J, Oqgp" I <"Cequwvke"pgwtq o c o vtgc v o gpv" o qfcnkvgu" Uwtigt{ " gamma-knife or observation? **Cevc"Qvqnet{piqn"Uwrn** 543: 34–37, 2000
- 3290" Owcegxke" C." Lguu/ J g o r gp" C." Vqpp" LE." Y q y tc" D<" Enkpkcn" quality standards for gamma knife radiosurgery—the Munich protocol. **Cevc"Pgwtqejkt"Uwrn** ;3<25–32, 2004
- 32:0" Owcegxke" C." Lguu/ J g o r gp" C." Vqpp" LE." Y q y tc" D<" Tguwvu"qh" outpatient gamma knife radiosurgery for primary therapy of acoustic neuromas. **Cevc"Pgwtqejkt"Uwrn** 91:75–78, 2004
109. Myrseth E, Møller P, Pedersen PH, Vassbotn FS, Wentzel-Larsen T, Lund-Johansen M: Vestibular schwannomas: clinical results and quality of life after microsurgery or gamma knife radiosurgery. **Pgwtqwtigt** 56:927–935, 2005
110. Myrseth E, Møller P, Wentzel-Larsen T, Goplen F, Lund-Johansen M: Untreated vestibular schwannomas: vertigo is a powerful predictor for health-related quality of life. **Pgwtq/ uwtigt** 59:67–76, 2006
111. Myrseth E, Pedersen PH, Møller P, Lund-Johansen M: Treatment of vestibular schwannomas. Why, when and how? **Cevc"Pgwtqejkt"Ykgp+** 149:647–660, 2007
112. Nedzelski JM, Chiong CM, Cashman MZ, Stanton SG, Rowed DW: Hearing preservation in acoustic neuroma sur-gery: value of monitoring cochlear nerve action potentials. **Qvqnet{piqn"Jgcf"Pgem"Uwti** 111:703–709, 1994
113. Nicoucar K, Momjian S, Vader JP, De Tribolet N: Surgery for large vestibular schwannomas: how patients and surgeons perceive quality of life. **J Neurosurg** 105:205–212, 2006
114. Nondahl DM, Cruickshanks KJ, Dalton DS, Klein BE, Klein R, Schubert CR, et al: The impact of tinnitus on quality of life in older adults. **L"Co" Cefc" Cwfkqn** 18:257–266, 2007
115. Ogunrinde OK, Lunsford DL, Kondziolka DS, Bissonette DJ, Flickinger JC: Cranial nerve preservation after stereotactic radiosurgery of intracranial acoustic tumors. **Uvgtgqvce" HWpev"Pgwtqwti** 64 *Uwrn<3<87–97, 1995
116. Okunaga T, Matsuo T, Hayashi N, Hayashi Y, Shabani HK, Kaminogo M, et al: Linear accelerator radiosurgery for vestibular schwannoma: measuring tumor volume changes

- on serial three-dimensional spoiled gradient-echo magnetic resonance images. **J Neurosurg** 103:53–58, 2005
- 3390 Qquvdpdtkpm T." Oqnn J C." Guukpm/Dqv ON< Vjg/GS/7F" cpf the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. **L' Enkp' Grkfgo kqn** 55: 791–799, 2002
118. Oostenbrink R, Oostenbrink JB, Moons KG, Derksen-Lubsen G, Essink-Bot ML, Grobbee DE, et al: Cost-utility analysis of patient care in children with meningeal signs. **Kpv' L' Vgejppq' Cuuguu' J gcnvj' Ectg** 18:485–496, 2002
119. Paek SH, Chung HT, Jeong SS, Park CK, Kim CY, Kim JE, et al: Hearing preservation after gamma knife stereotactic radiosurgery of vestibular schwannoma. **Ecepgt** 104:580–590, 2005
- 3420 Rgtt{ "C." I kcpkp' E." Tci jxcpx' T." Ue jgkvjcwgt' D Y." Dcpgtlgg' T." Octi tch' N." gy' cn' C i itguukxg' r jgpqv{ rke' cpf' i gppv{ rke' hgc- tures in pediatric and NF2-associated meningiomas: a clinico- pathologic study of 53 cases. **L' Pgwtrcqvjqn' Gzr' Pgwtn** 60: 994–1003, 2001
- 3430 Rgtt{ "DR." I cpv| "DL." Twdkpuvqk' LV< Ceqwuvke' pgwtq o cu' kp' vjg' elderly. **Qvqn' Pgwtrqvqn** 22:389–391, 2001
- 3440 Rqnqem' DG." Ftkueqnn' EN." Hqqv' TN." Nkpm' OL." I qto cp' FC." Bauch CD, et al: Patient outcomes after vestibular schwannoma management: a prospective comparison of microsurgical resection and stereotactic radiosurgery. **Pgwtrqwtigt{** 59: 77–85, 2006
- 3450 Tcwv' XX." Y cnuj' TO." Dcvj' CR." Dcepg' ON." I wjc' C." Vcvqt' CH, et al: Conservative management of vestibular schwannomas - second review of a prospective longitudinal study. **Enkp' Qvqnet{piqn' Cnnkf' Uek** 29:505–514, 2004
- 3460 Tgkogt' L." I kni' M." Mctqy' C." Guugt' L." Htcepmg' I J< J gcnvj/ related quality of life in blepharospasm or hemifacial spasm. **Cevc' Pgwtn' Uecpf** 111:64–70, 2005
- 3470 Tqejc/Hknj' RC." I jgtrgnk' LN." fg' Ukswgkte' LV." Tedgnnq' I F< Post-craniotomy headache: characteristics, behaviour and effect on quality of life in patients operated for treatment of supratentorial intracranial aneurysms. **Egrjcncnik** 28:41–48, 2008
126. Rosenberg SI: Natural history of acoustic neuromas. **Nct{p/ iqueqrg** 110:497–508, 2000
127. Ryzenman JM, Pensak ML, Tew JM Jr: Headache: a quality of life analysis in a cohort of 1,657 patients undergoing acoustic neuroma surgery, results from the acoustic neuroma association. **Nct{piqueqrg** 115:703–711, 2005
- 34:0 Uco k' O." I gticpx' X." Uco k' C< K o rtxgf' rtgugtxcvkp' qh' hearing and facial nerve function in vestibular schwannoma surgery via the retrosigmoid approach in a series of 200 patients. **J Neurosurg** 105:527–535, 2006
129. Sampath P, Holliday MJ, Brem H, Niparko JK, Long DM: Facial nerve injury in acoustic neuroma (vestibular schwannoma) surgery: etiology and prevention. **J Neurosurg** 87:60–66, 1997
130. Sanchez GB, Kaylie DM, O'Malley MR, Labadie RF, Jackson CG, Haynes DS: Chemical meningitis following cerebello-pontine angle tumor surgery. **Qvqnet{piqn' Jgcf' Pgem' Uwti** 138:368–373, 2008
- 3530 Ugnk{ c' V." J cv{ coc' V." Ujko c owt' P." Uw| wmk' U< C" eq o rtg- hensive classification system of vestibular schwannomas. **J Enkp' Pgwtrqek** 7:129–133, 2000
- 3540 Ugnej' OV." Rgftquq' C." Ngg' UR." Uqndgti' VF." Cic| ct{ cp' P." Ecdecvp/ Cycopi' E." gy' cn' Uvgtgqcevke' tcfkqvjgtr' { "hqt' vjg' treatment of acoustic neuromas. **J Neurosurg** 101 *Uwrn' 5< 362–372, 2004
133. Seol HJ, Kim CH, Park CK, Kim CH, Kim DG, Chung YS, et al: Optimal extent of resection in vestibular schwannoma surgery: relationship to recurrence and facial nerve preservation. **Pgwtn' Ogf' Ejk' *Vqm{ q' 68<** 176–181, 2006
134. Sheehan JP: Linear accelerator radiosurgery for vestibular schwannomas. **J Neurosurg** 105:655–656, 2006
135. Shelton C: Unilateral acoustic tumors: how often do they recur after transabyrinthine removal? **Nct{piqueqrg** 105:958–966, 1995
136. Shirato H, Sakamoto T, Sawamura Y, Kagei K, Isu T, Kato T, et al: Comparison between observation policy and fractionated stereotactic radiotherapy (SRT) as an initial management for vestibular schwannoma. **Kpv' L' Tc fkc' Qpeqn' Dkqn' Rj {u** 44:545–550, 1999
137. Shuto T, Inomori S, Matsunaga S, Fujino H: Microsurgery for vestibular schwannoma after gamma knife radiosurgery. **Cevc' Pgwtrqek' * Ykpp** 150:229–234, 2008
138. Silverstein H, Rosenberg SI, Flanzner JM, Wanmaker HH, Ugkf o cp' OF< Cp' cni qtkvj o "hqt' vjg' o cpcig o gpv' qh' ceqwuvke' neuromas regarding age, hearing, tumor size, and symptoms. **Qvqnet{piqn' Jgcf' Pgem' Uwti** 108:1–10, 1993
139. Smouha EE, Yoo M, Mohr K, Davis RP: Conservative management of acoustic neuroma: a meta-analysis and proposed treatment algorithm. **Nct{piqueqrg** 115:450–454, 2005
- 3620 Upkm' CH." xcp' Fwklpjxgp' PV." O {ncpwu' GC." Etg ogtu' E Y< Estimated cost-effectiveness of active middle-ear implantation in hearing-impaired patients with severe external otitis. **Ctej' Qvqnet{piqn' Jgcf' Pgem' Uwti** 132:1210–1215, 2006
- 3630 Uqpi' F [." Y knkc o u' LC." Htcevkpcvgt' uvgtgqvcevke' tcfkqvgt- gery for treatment of acoustic neuromas. **Uvgtgqvcev' Hwpev' Neurosurg** 73:45–49, 1999
- 3640 Urcv| " CN." \cmt| gyumc' LO." Mc{ " GL< Fgekukqp' cpcn{ uku' qh' medical and surgical treatments for trigeminal neuralgia: how patient evaluations of benefits and risks affect the utility of treatment decisions. **Rckp** 131:302–310, 2007
- 3650 Urkign o cp' T." Nkfct' \." I qh o cp' L." Cng| tc' F." J cfcpk' O." Pfeffer R: Linear accelerator radiosurgery for vestibular schwannoma. **J Neurosurg** 94:7–13, 2001
144. Stangerup SE, Caye-Thomasen P, Tos M, Thomsen J: Change in hearing during 'wait and scan' management of patients with vestibular schwannoma. **L' Nct{piqn' Qvqn** 122: 673–681, 2008
145. Stangerup SE, Caye-Thomasen P, Tos M, Thomsen J: The natural history of vestibular schwannoma. **Qvqn' Pgwtrqvqn** 27: 547–552, 2006
- 3680 Uvgtmgtu' LO." Oqtkuq' I C." Uvgtmgtu' Q." Gn/ Fkpg' O O< Preservation of facial, cochlear, and other nerve functions in acoustic neuroma treatment. **Qvqnet{piqn' Jgcf' Pgem' Uwti** 110:146–155, 1994
147. Strasnick B, Glasscock ME III, Haynes D, McMenomey SO, Minor LB: The natural history of untreated acoustic neuromas. **Nct{piqueqrg** 104:1115–1119, 1994
- 36:0 Uwdtco cpk o " M." Gkmndqo " T J." Geigt' MO." Cvcnu' OF< Unilateral profound hearing loss and the effect on quality of life after cerebellopontine angle surgery. **Qvqnet{piqn' Jgcf' Pgem' Uwti** 133:339–346, 2005
149. Szeifert GT, Figarella-Branger D, Roche PH, Régis J: Histo- pathological observations on vestibular schwannomas after Gamma Knife radiosurgery: the Marseille experience. **Pgw/ tqejktwtik** 50:327–337, 2004
150. Tan EK, Fook-Chong S, Lum SY, Thumboo J: Validation of a short disease specific quality of life scale for hemifacial spasm: correlation with SF-36. **L' Pgwtn' Pgwtrqwti' Ru{ ejk/ cvt{** 76:1707–1710, 2005
151. Thomas C, Di Maio S, Ma R, Vollans E, Chu C, Clark B, et al: Hearing preservation following fractionated stereotactic radiotherapy for vestibular schwannomas: prognostic implications of cochlear dose. **J Neurosurg** 107:917–926, 2007
152. Tschudi DC, Linder TE, Fisch U: Conservative management of unilateral acoustic neuromas. **C o' L' Qvqn** 21:722–728, 2000
- 3750 Vwhctgnk' F." Ognk' C." Cngukk' C." Fg' Cpignku' G." Dcftceeq' E." Falcioni M, et al: Quality of life after acoustic neuroma surgery. **Qvqn' Pgwtrqvqn** 27:403–409, 2006
- 3760 xcp' Gem' CV." J qtu o cp' I C< kpetgcugf' rtgugtxcvkp' qh' functional hearing after gamma knife surgery for vestibular schwannoma. **J Neurosurg** 102 Uwrn' 204–206, 2005
- 3770 xcp' J qwygnkipg' J E." Ctgpfu' NT." Uvklpgp' V< C fxcpegf'

- methods in meta-analysis: multivariate approach and meta-regression. *Uvev* **Ogf 21**:589–624, 2002
- 3780" xcp" Tqklgp" N." Pklv" J I." Cxg|ccv" EL." Mctnuuqp" I." Nkpswkuv" C, Pauw KH, et al: Costs and effects of microsurgery versus radiosurgery in treating acoustic neuroma. *Cevc* **Pgwtqejkt** ***Ykqp** **139**:942–948, 1997
- 3790" Xctnqvq" LO." Ujtkxg" FE." Cngzcpfgt" G"KKK." Mqq{" J O." Dncem" PM, Loeffler JS: Fractionated stereotactic radiotherapy for the treatment of acoustic neuromas: preliminary results. *Kpv* **L" Tcfkcv" Qpeqn" Dkqn" Rj{u 36**:141–145, 1996
- 37:0" Ycem{ o" RC<" Uvgtgqcevke" tcfkquwtigt{" oketquwtigt{" cpf" expectant management of acoustic neuroma: basis for informed consent. *Qvqnet{piqn" Enkp" Pqtvj" Co 38:653–670, 2005*
- 37:0" Ycem{ o" RC." Twpig/Uc o wgnuqp" EN." Rqgvmtg" FO." Okejgn" OC." Cmch" HO." Dwti" NU." gv" cn<" I co oc" mpkhg" tcfkquwtigt{" hqt" acoustic neuromas performed by a neurotologist: early experiences and outcomes. *Qvqn" Pgwtqvqn 25*:752–761, 2004
- 3820" Ycnuj" TO." Dcvj" CR." Dcepg" ON." Mgnngt" C." Twvmc" LC<" Eqp/ sequences to hearing during the conservative management of vestibular schwannomas. *Net{piqueqrq 110*:250–255, 2000
- 3830" Ycnuj" TO." Dcvj" CR." Dcepg" ON." Mgnngt" C." Vcvqt" E J." Twvmc" LC<" Vjg" tqng" qh" eqpugtxcvkg" ocpicogpv" qh" xguvkdwnct" Is there a role for conservative management? *Tgx" Nct{piqn" Qvqn" Tjlpqn" Dqtf+ 121*:21–26, 2000
- 3840" Ycnuj" TO." Dcvj" CR." Dcepg" ON." Mgnngt" C." Vcvqt" E J." Twv/ mc" LC<" Vjg" tqng" qh" eqpugtxcvkg" ocpicogpv" qh" xguvkdwnct" schwannomas. *Enkp" Qvqnet{piqn" Cmkgf" Uek 25*:28–39, 2000
163. Ware JE: Measuring patients' views: the optimum outcome measure. *DOL 306*:1429–1430, 1993
164. Warrick P, Bance M, Rutka J: The risk of hearing loss in non-growing, conservatively managed acoustic neuromas. *Co" L" Qvqn 20*:758–762, 1999
- 3870" Ygdgt" FE." Ejcp" CY." Dwuukgtg" OT." Jctuj" I T" KX." Cpew/ kiewicz M, Barker FG II, et al: Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicity. *Pgwtquwtigt{ 53*:577–588, 2003
- 3880" Ykpfgnu" PL." xcp" Jcgutgi v" C." Mpwkupji j" Pgxgp" C." Urkp/ jxgp" R." \kv o cp" HI." Cuugpfgnhv" YL." gv" cn<" Ej tqpk" htgswgpn" headache in the general population: comorbidity and quality of life. *Egrjcncnik 26*:1443–1450, 2006
- 3890" Ykgv" TL." \crrkc" LL." Jgejv" EU." QüEqppqt" EC<" Eqpugtxcvkg" management of patients with small acoustic tumors. *Net{p/ iqueqrq 105*:795–800, 1995
- 38:0" Yqytc" D." Owcegxe" C." Lguu/ J go rgp" C." J go rgn" LO." OÄnngt/ Schunk S, Tonn JC: Outpatient gamma knife surgery for vestibular schwannoma: definition of the therapeutic profile based on a 10-year experience. *J Neurosurg 102* ***Uwrrn**<114–118, 2005
169. Yamasoba T, Kurita H, Ito K, Mizuno M, Nakamura M, Uwicucyc" O." gv" cn<" Cwfkvtq{ "hkpfpki u" chvgt" uvgtgqcevke" tcfkq- surgery in acoustic neurinoma. *Umwm" Dcug" Uwti 6*:163–167, 1996
170. Yang SY, Kim DG, Chung HT, Park SH, Paek SH, Jung HW: Evaluation of tumour response after gamma knife radiosurgery for residual vestibular schwannomas based on MRI morphological features. *L" Pgwtqn" Pgwtquwti" Ru{ejkvt{ 79*: 431–436, 2008

Manuscript submitted December 1, 2009.

Ceeegrvgf" Ocj" 3." 42320

Please include this information when citing this paper: pub- nku jgf" qpnpkg" Crtkn" 38." 4232=" FQK<" 320539314232050LPU2; 3: 240

Address correspondence to: John Y. K. Lee, M.D., Department of Neurosurgery, Hospital of the University of Pennsylvania, 3 Silverstein, 3400 Spruce Street, Philadelphia, Pennsylvania 19104. email: leejohn@uphs.upenn.edu.